Title
A conserved Leishmania hypothetical protein evaluated for the serodiagnosis of canine and human visceral and tegumentary leishmaniasis, as well as a serological marker for the posttreatment patient follow-up
Date Issued
01 November 2018
Access level
metadata only access
Resource Type
journal article
Author(s)
Ribeiro P.
Dias D.
Lage D.
Costa L.
Salles B.
Steiner B.
Ramos F.
Lima M.
Santos T.
Chaves A.
Fujiwara R.
Bueno L.
Caligiorne R.
de Magalhães-Soares D.
Silveira J.
Machado-de-Ávila R.
Gonçalves D.
Coelho E.
Publisher(s)
Elsevier Inc.
Abstract
In the present study, a conserved Leishmania hypothetical protein, LiHyE, was evaluated for the serodiagnosis of leishmaniasis. Results showed that it presented high sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) to serologically identify visceral leishmaniasis (VL) dogs when 40 positive sera and 95 cross-reactive samples were used. rLiHyE also showed the best results of sensitivity, specificity, PPV, and NPV to identify tegumentary leishmaniasis (TL) and VL patients when 45 leishmaniasis patients’ sera and 90 cross-reactive samples were used. Results were better in comparison to those obtained when rA2 or Leishmania antigenic extract was employed as controls. The posttreatment follow-up showed that rLiHyE-specific antibodies declined significantly after the end of treatments, and a predominance of the IgG2 subclass was found in comparison to IgG1 levels in both TL and VL patients. In conclusion, rLiHyE can be considered a candidate for the serodiagnosis of canine and human leishmaniasis.
Start page
196
End page
203
Volume
92
Issue
3
Language
English
OCDE Knowledge area
Biología celular, Microbiología Enfermedades infecciosas
Scopus EID
2-s2.0-85048877116
PubMed ID
Source
Diagnostic Microbiology and Infectious Disease
ISSN of the container
07328893
Sponsor(s)
This work was supported by the Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT Nano-Biofar) , FAPEMIG ( CBB-APQ-00819-12 and CBB-APQ-01778-2014 ), and CNPq ( APQ-482976/2012-8 , APQ-488237/2013-0 , and APQ-467640/2014-9 ). EAFC is a grant recipient of CNPq . MACF is a grant recipient of CAPES/FAPEMIG .
Sources of information: Directorio de Producción Científica Scopus